ArticleInterventional pain medicine2026
Scar neuroma infiltration to treat post-surgical first bite syndrome.
Article in Interventional pain medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: First bite syndrome (FBS) is an uncommon but often debilitating complication after head and neck surgeries, particularly those that involve or affect the cervical sympathetic chain. FBS is characterized by sudden, severe, and often cramping or electric shock-like pain in the region of the parotid gland, which may become chronic. Current treatment recommendations for FBS-related pain include pharmacologic agents, muscle relaxants, anti-neuropathic and anti-inflammatory agents, oral rehabilitation, and infiltration of anesthetics and botulinum toxin; most patients require systemic analgesics. Although some patients experience a response to pharmacological agents and local infiltration of the salivary glands, a subset develops intractable pain. For some patients, escalating dosages of opiate analgesics are the only management option. Objectives: Here, we report a series of five consecutive patients with intractable FBS-related pain that was refractory to conventional treatment. In each case, we found a localized point of mechanical allodynia overlying the surgical scar. Even light stimulation of this focal point elicited the symptoms described during initial mastication. Methods: Identification of the scar neuroma within the surgical field in these patients provided a potential diagnostic and therapeutic target for this condition. We performed a scar infiltration with a mix of 1.75 mL of bupivacaine 0.25% and 0.25 mL of 40 mg/mL triamcinolone. The quality and duration of pain relief following the treatment are described in this report. Results: All five patients experienced sustained analgesia of over 3 months in duration, with immediate improvement in quality of life because of controlled pain and improved oral feeding. Conclusions: Scar neuroma infiltration was found to be a minimally invasive, efficient, and cost-effective treatment, and overall patient satisfaction was very high. To our knowledge, this is the first report using this therapy to treat FBS-related pain. The novel approach shows promise in a limited number of patients cases and warrants further investigation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.